WdiologonewMedical Report:  Fish Oil

Fish oil has long been lauded as a great source of heart-healthy fat and new research from Harvard University shows that it also helps the body reduce inflammation. The body converts an active ingredient found in fish oils, known as DHA, into a chemical called Resolvin D2.

Researchers studied the effects of this chemical on mice suffering from full-body inflammation and found that Resolvin D2 was able to dramatically reduce this inflammation and increase survival rate. Inflammation occurs when the body’s natural defenses against infections are mistakenly directed at healthy tissue. This means that in order to combat inflammation, most drugs currently used must also suppress the immune system , something that can be dangerous for patients whose bodies are already weakened by infection. In the study, they found that Resolvin D2 was not only a powerful anti- inflammatory, but it was able to reduce inflammation without affecting the immune system. Because of this, researchers feel that this active ingredient in fish oil has great potential as a treatment for rheumatoid arthritis and stroke.

WATCH VIDEO:  http://www.wdio.com/article/stories/S1221731.shtml?cat=10360

TLCJoin us for a memorable evening that will raise funds to benefit research and education for Lyme disease and other tick-borne illnesses. The evening will feature cuisine by several of New York City’s finest restaurants, a variety of spirits, exciting live and silent auctions and an elaborate sweepstakes.

HONORING DANIEL CAMERON, MD,  MPH 2009 Humanitarian Award

ANN F CORSON, MD 2009 Physicians Training Program Impact Award

PETER HILF 2009 Vision of Hope Award

Peter Alexander, NBC News Correspondent Emcee

Thursday, November 5, 2009 6:00PM – 10:00PM

The Edison Ballroom 240 West 47th Street New York City

Advance ticket: $200 (by November 3, 2009) Ticket at the door: $250 (if available) VIP Ticket: $350 (includes name listing in the event program and invitation to private VIP reception) Business Attire For more information and sponsorship opportunities, contact Arienne Orozco at arienne@poweredbyprofessionals.com

TURN THE CORNER FOUNDATION 2009 COURAGE AWARDS Lyme disease masquerades many different chronic illnesses. Thousands of people are misdiagnosed with arthritis, chronic fatigue, multiple sclerosis or Alzheimer’s disease. Turn the Corner is proud to present the 2009 Turn the Corner Courage Awards to several individuals who have bravely fought against this devastating disease:

Thomas Balsamo, Monica S. Bolesta, PhD, Doug Fearn Toren, Gordon Kutnick, Richard E. LaMotta, Judy Landis Setting, Gail Sheffer, Gail Urbach

Executive Board Staci Grodin President Charles P. Balducci Vice President Stephanie W. Spar Vice President of Program Development Richard Grodin Treasurer Alyssa Sokoloff Secretary Board Anthony Addison Michael P. Beach Faythe Goldman Matt Jacobs Nan Kurzman Danny Lirtzman Lisa Gitnik Maloul Lorrie Nadel Edward G. O’Connell Daniel Pine Stephen Soleymani Advisory Board Kenny Dichter Nancy Fitzsimmons Damon Giglio Jesse Itzler Eric S. Kratz Brooke Landau Leo J. Shea III , Ph.D. Gary Sommers

Medical Advisory Board Gregory Paul Bach, DO, FAAIM Sabra M. Bellowin, MD Kenneth A. Bock, MD Stephen J. Bock, MD Joseph J. Burrascano JR., MD Robert C. Bransfield, MD, FAPA Daniel Cameron, MD, MPH Ingeborg S. Dziedzic, MD Andrea Gaito, MD Nick S. Harris, Ph.D., ABMCI Richard Horowitz, MD Joseph G. Jemsek, MD, FACP Charles Ray Jones, MD Alan B. MacDonald, MD Jeffrey A. Morrison, MD, CNS Stephen E. Phillips, MD Bernard D. Raxlen, MD Virginia T. Sherr, MD Gerald T. Simons, PA-C Harold A. Smith, MD

Gala Committee Faythe Goldman Chairperson Virginia Anez Cathy Balsamo Lauren Borish Janet Brand Cameron Buzzeo Ali & Michael Cammeyer Dolores Claesson Ann Patricia Coleman Cesar Diaz Dana L. Evans Sari & Steve Feinberg Laura Field Alexander Field Mara Heppen Merrilee Hesterfer-Diaz Allie Hill Carolyn Joseph Nicole Kalish Katherine Kane Heather Levine Myriam Munoz Daniel Paris Jeana Payne Barbara Perry Staton Rabin Sharon Richter, MS, RD, CDN Chad Rose Melissa Roth Kathy Rucker Barbara Shelton Alexandra Spar Renee Vallone Alexis Weber

By The Associated Press (AP)

A look at key issues in the health care debate:

THE ISSUE: How much do Americans who have employer-sponsored health insurance pay in premiums? What do their employers pay? Would that change if the system is overhauled?

THE POLITICS: Health care costs have been increasing. For Americans and the businesses that insure most of them, that translates into higher insurance premiums. The average premium cost for employer-provided insurance has doubled since 2000. These days, coverage for an individual with employer-provided insurance costs on average $4,824 a year, with the employee paying $779 of that amount, according to a 2009 survey by the Kaiser Family Foundation and Health Research and Educational Trust. For a family plan, the premium is $13,375 with the employee paying $3,515. Under current law, the Congressional Budget Office estimates that in 2016 average premiums for employer-based insurance will rise to about $7,500 for a single policy and about $19,000 for a family policy.

WHAT IT MEANS: Numerous factors will affect the cost of insurance under proposed health care bills, making their impact hard to predict. But President Barack Obama has vowed to lower the cost of health care. A recent study by America’s Health Insurance Plans said the most moderate of the Democrats’ health insurance plans would increase premiums. But the study only examined select aspects of the bill and ignored provisions aimed at making health care more affordable. The legislation would set up exchanges where companies would compete for customers. It also would provide subsidies for lower-income people.

_ Jim Kuhnhenn

By David Liu and editing by Rachel Stockton

Editor’s note:

New York Times reported just minutes ago that President Barack Obama’s daughters, Malia, 11 and Sasha, 8 have just been vaccinated against H1N1 or swine flu. The White House released the news to show the public that H1N1 vaccine is safe.

There should be no doubt the vaccine is safe for healthy people as trials have demonstrated. The majority of the citizens do not want H1N1 largely because they believe the drug is not safe. Their concern is in a sense justified because it actually remains unknown whether the h1n1 flu vaccine is safe for those who have medical conditions and pregnant women because trial conducted thus far involved only healthy individuals.

The efficacy of the vaccine is another issue. The Centers for Disease Control and Prevention said the h1n1 vaccine is made in the same way other seasonal flu vaccines are made each year. Because of this, CDC health officials said the safety and efficacy should be the similar if not the same to that of seasonal flu. But seasonal flu often does not match the circulating virus strain and thus the efficacy is often not as high as thought.

In any case, no matter you have received flu vaccines for seasonal flu and or H1N1, make sure that you take high doses of vitamin C and vitamin D because these health supplements have proved effective in preventing and treating colds and flu.

The following is an article about a study showing that high doses of vitamin C help colds and flu.

One study suggests that you may be better off taking mega doses of vitamin C during the winter to prevent and even treat flu, including h1n1 flu regardless of your immunization status.

The study published in Oct 1999 in the Journal of Manipulative and Physiological Therapeutics, found that taking 1000 milligrams of vitamin C, or ascorbic acid, reduced flu and cold symptoms compared to use of pain relievers and decongestants.

Gorton HC and Jarvis K, whose affiliation was unknown (from the abstract of the report) enlisted 463 students, aged 18 and 30, as controls and 252 students in the same age group as test subjects.

They tracked the number of reports of cold and flu symptoms among the test subjects in 1991 and reports of similar symptoms among the controls in 1990. The controls were treated with pain relievers and decongestants while the test subjects were given 1000 mg each hour for the first six hours of reporting symptoms; then three times each day for the next three days.

The researchers found that reported flu and cold symptoms in the test group decreased 85 percent, compared with the control group.

They concluded that mega doses of vitamin C administered before and after the appearance of cold and flu symptoms relieved and prevented said symptoms.

This is not the only study that has concluded that taking high doses of vitamin C prevents and helps victims of the flu and colds. Vitamin C has been known to boost one’s immunity against these illnesses.

Those who bet their winter on the seasonal flu and or h1n1 flu vaccine need to remember that these vaccines are often not as effective as thought. Chances are very good that if you get the vaccine you will still get the flu. So do not forget to take high doses of vitamin C in the winter. Another, possibly more effective, supplement you can enlist to protect against flu is Vitamin D, in high doses.



KIM’S NOTES:  I plan on attending the November 8th, 2PM show.  Please come and bring ten of your friends!  We need to fill every seat! //Kim


WEBWIRE – Monday, October 26, 2009
Contact Information
Monique Dubos
Event manager
Minnesota Lyme Action Support Group

Minnesota Film Arts is proud to present the Lyme disease documentary “Under Our Skin,” co-sponsored by the Minnesota Lyme Action Support Group. Show days and times are: November 8, 2:00 pm and 5:00 pm, and November 9 and 10, 7:30 p.m., at the Oak Street Cinema, 309 Oak St in Minneapolis. The Event is Part of an Effort to Pass Legislation to Allow Patients to Choose Long-term Lyme Disease Antibiotic Therapy

The screenings are part of an effort to raise awareness and help pass Minnesota Senate bill SF1631, which will allow patients with Lyme disease other tick-borne diseases and their doctors– not insurance companies – to decide what treatment protocol to follow.

Jordan Fisher Smith, who tells his own harrowing story in the film, will emcee the Nov 8 and 9 showings. State legislators Ray Vandeveer and John Ward will talk briefly about the legislation before the shows on Nov 8. Dr. Elizabeth Maloney, MLASG medical consultant, will be on hand for questions after all screenings. Jordan Fisher Smith and Dr. Maloney will be available to media 45 minutes before show times, or by appointment.

Lyme disease is a complex disease with complicated issues surrounding it. Here are some of the basics:

* Lyme disease is the fastest growing vector-borne disease in the United States. Minnesota ranks 8th, with 1,282 cases reported in 2008.
* The CDC estimates the number to be ten times that, making LD bigger than West Nile and Avian flu combined.
* 1 in 3 deer ticks in Minnesota carry the Lyme bacteria, according to the MN Dept of Health.
* Lyme cases have spiked 450% in Minnesota from 1998 – 2008.
* Tests for LD are highly inaccurate and result in false negatives; insurance companies then use these results to deny care.
* Patients are often denied much-needed antibiotic treatment by doctors who are misinformed about the disease or fear reprisal from state medical boards.
* Each year thousands go undiagnosed or misdiagnosed, told that their symptoms are “all in their head.”

“Under Our Skin” follows patients and physicians as they battle for their lives and livelihoods, bringing into focus a haunting picture of our health care system and its inability to cope with a silent terror under our skin.

The Minnesota Lyme Action Support Group is a non-profit organization working toward increased awareness and prevention of Lyme disease, as well as much-needed research into the causes and complications of tick-borne diseases.

The Minnesota Lyme Action Support Group also provides educational opportunities for physicians, advocacy for patients, information on tick-borne diseases, and support to those infected with Lyme disease.

Public release date: 27-Oct-2009
Contact: Randi Triant
Tufts University, Health Sciences

Tufts CTSI and Tufts University receive 4 NIH supplemental grant awards

The Tufts Clinical and Translational Science Institute (CTSI) and Tufts University today announced they are the recipients of four supplemental grant awards from the National Institutes of Health. These new awards, totaling approximately $1.73 million, are supplements to the original Clinical and Translational Science Award (CTSA) grant, UL1 RR025752 that Tufts University received in 2008 from the National Center for Research Resources.

“Community Engagement Research” is a two-year project that will expand the scope of Tufts CTSI’s current community engagement program by enhancing the ability of community partners to participate more effectively in the development of research plans and outcomes. Begun in September 2009, the project has already established an alliance between the Tufts CTSI, the Harvard Clinical and Translational Science Center, and two pivotal community partners, the Center for Community Health Education, Research, and Service (CCHERS) and the Immigrant Service Providers Group/Health (ISG/H). This alliance is creating a curriculum and evaluation for a self-study and face-to-face program entitled “Fostering Community Partners in Translational Research (FCPTR)” that will target community agencies and health centers. The Program Director is Laurel Leslie, MD, MPH, Associate Professor of Medicine at Tufts University School of Medicine.

“Improving BPD Predictors and Outcomes for Clinical Trials” builds on prior landmark research that identified a constellation of signs and symptoms in high risk newborns to accurately define bronchopulmonary dysplasia (BPD) and predict the subsequent development of chronic respiratory morbidity (CRM) later in childhood and adolescence. While treatment with recombinant human superoxide dismutase to premature newborns has been proven to have a 55% reduction in CRM compared to placebo controls, current definitions of BPD may be unreliable predictors of CRM and a more robust reduction in CRM is needed. Superoxide dismutase is an enzyme that converts superoxide radicals (highly reactive oxygen molecules produced during metabolism and capable of damaging body tissues) into less toxic agents. This one-year study is a prospective, longitudinal, observational study in 85 preterm infants 24-29 weeks gestation. The Program Director is Jonathan Davis, MD, Chief of Newborn Medicine, The Floating Hospital for Children at Tufts Medical Center, Program Director at the Clinical and Translational Research Center, and Professor of Pediatrics, Tufts University School of Medicine. Partners in this study include Brigham and Women’s Hospital (Harvard University), Beth Israel Hospital (Harvard University), Nationwide Children’s Hospital (Ohio State), and King’s College in London.

“Searching for Persistence of Infection in Lyme Disease” is a highly innovative Bench-to- Bedside research project that could have an extraordinarily significant impact on the field of Lyme disease. Although antibiotic therapy is clinically effective in treating the symptoms of Lyme disease for most patients early in the course of disease, a significant number of patients who receive therapy report persistent symptoms. A range of theories have been proposed for why this occurs. Moreover, commonly available tests for human Lyme disease are not able to determine persistent infection after antibiotic therapy. Program Director, Linden Hu, MD (Associate Professor of Medicine, Tufts University School of Medicine and Associate Professor of Microbiology, Sackler School of Biomedical Graduate Sciences) has begun an unconventional study examining whether xenodiagnosis (the feeding of uninfected Ixodes ticks on infected animals) can be used to determine when persistent infection occurs in humans. Xenodiagnosis has been used for other difficult to diagnose diseases such as Chagas disease and can sometimes definitively identify the presence of an organism in animals where other techniques cannot. Whether xenodiagnosis is effective in humans is unknown. This two-year project seeks to test the utility of xenodiagnosis for identifying persistence of B. burgdorferi, the spirochetal bacteria that cause Lyme disease, after antibiotic treatment of the disease. Dr. Linden’s team will test subjects with elevated C6 antibody levels or persistent symptoms after antibiotic therapy and patients with Lyme arthritis. Evidence that B. burgdorferi can be identified by xenodiagnosis after antibiotic therapy in subjects with continued symptoms would significantly change the current paradigm for potential mechanisms of disease and provide researchers and clinicians with a novel tool for identifying patients with persistent infection.

Tufts CTSI currently has a Pilot Studies Program that funds new interdisciplinary research teams, seeds novel ideas, and provides the means to acquire necessary preliminary data for larger, multi-year grant applications. A new supplemental project, The Pilot Project Mechanism, is led by Susan K. Parsons, MD, MRP, Director, The Health Institute, Institute for Clinical Research and Health Policy Studies and Associate Professor of Medicine and Pediatrics, Tufts University School of Medicine, and Amy Yee, PhD, Professor of Biochemistry, Sackler School of Biomedical Graduate Sciences. This two-year project expands the current program to influence research not just within the Tufts enterprise, but also throughout the Commonwealth of Massachusetts and into New England via Tufts CTSI’s forty-three collaborating partners by soliciting interinstitutional and multidisciplinary applications. Many of the identified programs will hire and support undergraduate and graduate students and postdoctoral fellows, thereby creating jobs throughout New England and also increasing the pipeline for translational researchers.


About Tufts Clinical and Translational Science Institute (CTSI)

Tufts CTSI was established in August 2008 with Grant Number UL1 RR025752 from the National Center for Research Resources (NCRR), National Institutes of Health (NIH). A collaboration of organizations, founded by Tufts Medical Center and Tufts University, Tufts CTSI accelerates the translation of laboratory research into clinical use, medical practice and health policy. It connects people to research resources, consultation, and education, and fosters collaboration with scholars of all disciplines and with community members, with the ultimate goal of improving the health of the public. Website: www.tuftsctsi.org.

About NCRR and the CTSA Consortium

The National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH), provides laboratory scientists and clinical researchers with the tools and training they need to understand, detect, treat, and prevent a wide range of diseases. NCRR supports all aspects of clinical and translational research, connecting researchers, patients, and communities across the nation. Through programs such as the Clinical and Translational Science Awards, NCRR brings together innovative research teams and equips them with essential tools and critical resources needed to tackle the nation’s complex health problems.

About the NIH

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. Helping to lead the way toward important medical discoveries that improve people’s health and save lives, NIH scientists investigate ways to prevent disease as well as the causes, treatments, and even cures for common and rare diseases. Composed of 27 Institutes and Centers, the NIH provides leadership and financial support to researchers in every state and throughout the world. For more information about NIH and its programs, visit www.nih.gov.